Status:
RECRUITING
Comparative Efficacy of Intravenous Labetalol and Lignocaine in Mitigating Hemodynamic Responses to Laryngoscopy During Laparoscopic Cholecystectomy
Lead Sponsor:
Dr. Waseem Ullah
Collaborating Sponsors:
Hayatabad Medical Complex
Conditions:
Intubation
Anesthesia
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Laryngoscopy and intubation during laparoscopic cholecystectomy often cause sudden increases in heart rate and blood pressure, which can be harmful in some patients. Medications such as labetalol and ...
Detailed Description
Laparoscopic cholecystectomy is the standard surgical treatment for symptomatic gallstones. However, laryngoscopy and endotracheal intubation during anesthesia often trigger a sympathetic surge, resul...
Eligibility Criteria
Inclusion
- ASA Grade I and II
- Age 18 to 60 years
- Elective laparoscopic cholecystectomy
- Both genders
- Informed consent given
Exclusion
- Hypersensitivity to labetalol/lignocaine
- Hypertensive on antihypertensives
- ASA Grade III or more
- Cardiovascular, renal, hepatic, or endocrine issues
- Pregnant/lactating
- BMI ≥ 35
- Anticipated difficult airway
Key Trial Info
Start Date :
June 5 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2026
Estimated Enrollment :
116 Patients enrolled
Trial Details
Trial ID
NCT07192081
Start Date
June 5 2025
End Date
February 28 2026
Last Update
September 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hayatabad Med Complex
Peshawar, Khyber Pakhtunkhwa, Pakistan, 25000